New drug cocktail aims to cut bleeding and heart attacks in atrial fibrillation patients
NCT ID NCT03331484
First seen May 14, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study tested a combination of two drugs, rivaroxaban and ticagrelor, in 40 patients with atrial fibrillation who had a stent placed. The goal was to see if this combo causes less bleeding and prevents heart attacks or strokes better than current treatments. Patients took the drugs for one year, and researchers tracked bleeding events and heart-related outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban and Ticagrelor
What this could lead to
If successful, this could point toward a safer, more effective drug combination for managing heart disease in patients with atrial fibrillation after stent placement.
What could go wrong
This is a small, non-randomized study with only 40 participants, so results may not apply broadly. Bleeding risks remain a concern with these potent drugs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.